Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: borredo

"...I base this on what Swartz said at SH meeting. Which was a great indicator that no one picked up on: He said after settlement our share price should be $1.50 to $4.00 per share...."

I wasn't at the last SHM, but IMO anything Swartz does or says is pure theatre for the shareholder audience. In my perception, he has little basis for making such an estimation to shareholders, and if he does have basis, that makes me think he is closer to the TPL issues and strategies than he should be.

Gettin' testy....(sorry)

Regards

Share
New Message
Please login to post a reply